Beacon Pointe Advisors, LLC Crispr Therapeutics Ag Transaction History
Beacon Pointe Advisors, LLC
- $11.3 Billion
- Q3 2025
A detailed history of Beacon Pointe Advisors, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Beacon Pointe Advisors, LLC holds 12,826 shares of CRSP stock, worth $709,534. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,826
Previous 7,446
72.25%
Holding current value
$709,534
Previous $362,000
129.56%
% of portfolio
0.01%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CRSP
# of Institutions
548Shares Held
67.7MCall Options Held
3.5MPut Options Held
3.08M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl9.79MShares$541 Million4.45% of portfolio
-
Capital International Investors Los Angeles, CA5.65MShares$313 Million0.06% of portfolio
-
Orbis Allan Gray LTD Hamilton, D04.98MShares$276 Million1.8% of portfolio
-
State Street Corp Boston, MA4.01MShares$222 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.28MShares$182 Million0.13% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.32B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....